LiDCO Group plc : LiDCOrapid monitoring - part of a successful enhanced recovery programme following liver resection

05 June 2013

LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, announces that its LiDCOrapid monitor has been used successfully to monitor cardiac output and guide intravenous fluid therapy in a randomised clinical trial on enhanced recovery versus standard care following open liver resection.

This clinical trial involved 91 patients and was carried out at the Royal Surrey County Hospital and the results were published recently by the British Journal of Surgery (DOI: 10.1002/bjs.9165). The 91 patients were randomly allocated to receive standard care or an Enhanced Recovery Programme ("ERP"). The patients in the ERP were monitored using the LiDCOrapid system. LiDCOrapid is a hemodynamic monitoring system that uses a specific algorithm derived from the analysis of the pulse power of the arterial waveform to calculate the stroke volume from the heart. The principle behind using this method of measurement is that fluctuations in blood pressure about the mean are directly proportional to the stroke volume as shown by Rhodes and Sunderland in their publication, Arterial Pulse Power Analysis published in Update in Intensive Care Medicine, Springer, Berlin, 2005.

Overall, the trial confirmed that using an ERP that included goal directed fluid therapy (GDFT) monitored by the LiDCOrapid system reduces the length of stay by three days for patients undergoing open liver resection and post-operative complications were reduced (to 7% versus 27% in the control arm). This better care has led to an improvement in short term quality of life for the patients in the ERP GDFT arm of the trial.

Commenting on the publication of this clinical paper, Terry O'Brien, CEO of LiDCO, said:
"This study adds to the performance and outcomes evidence base supporting the advantages for use of the LiDCO's monitoring technology in high risk surgery patients. The ease of use of the system by healthcare professionals and benefits for patients gives us confidence that the LiDCOrapid system has the performance necessary to establish itself as the fluid monitoring system of choice in the fluid optimisation of high risk surgery patients both during and after major surgery. "

For further information, please contact:

About LiDCO Group Plc (www.lidco.com)

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals, to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre.

Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

Key Products:

LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%).

LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides:

• early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug
• quantification of hemodynamic response,
• guidance on effective delivery of fluids to ensure the right amount at the right time

LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.

LiDCO Unity Software: The software incorporated into LiDCOrapidv2 allows the LiDCOrapid monitor to co-display Covidien's level of consciousness parameter and add the convenience of CNSystem's* continuous non-invasive blood pressure monitoring. This will address a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors.

* CNAPTM is a trademark of CNSystems Medizintechnik AG.

All LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.

LiDCO Distribution Network:

LiDCO's strategy is to sell directly to hospitals in the UK and USA, and through a network of specialty critical care and anaesthesia distributors in the rest of the world.

LiDCO's sales office is in Cambridge, its manufacturing facility and headquarters are in London and its shares are traded on AIM.